Cargando…

Point prevalence of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma according to the number of cycles of R-CHOP chemotherapy

R-CHOP chemotherapy composed of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone which might increase the risk of Pneumocystis pneumonia in patients with non-Hodgkin lymphoma. We estimated the point prevalence of Pneumocystis pneumonia in non-Hodgkin lymphoma patients according...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Tark, Choi, Sang-Ho, Kim, Sung-Han, Jeong, Jin-Yong, Woo, Jun Hee, Kim, Yang Soo, Sung, Heungsup, Kim, Mi-Na, Yoon, Dok Hyun, Suh, Cheolwon, Lee, Sang-Oh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080131/ https://www.ncbi.nlm.nih.gov/pubmed/23053189 http://dx.doi.org/10.1007/s00277-012-1592-1

Ejemplares similares

Clinical characteristics of hospital-onset Pneumocystis pneumonia and genotypes of Pneumocystis jirovecii in a single tertiary centre in Korea
por: Kim, Tark, et al.
Publicado: (2015)

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
por: Yoo, Changhoon, et al.
Publicado: (2010)

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
por: Jang, Geundoo, et al.
Publicado: (2011)

A Case of Primary Adrenal Diffuse Large B-cell Lymphoma Achieving Complete Remission with Rituximab-CHOP Chemotherapy
por: Kim, Kyung Min, et al.
Publicado: (2009)

Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma
por: Cho, Hyungwoo, et al.
Publicado: (2016)

Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole used as First-Line Treatment for Pneumocystis jirovecii Pneumonia
por: Kim, Tark, et al.
Publicado: (2018)

A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas
por: Kim, Jeong Eun, et al.
Publicado: (2012)

ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
por: Park, Sang Hyoung, et al.
Publicado: (2006)

Relapse pattern and prognostic factors for patients with primary CNS lymphoma
por: Suh, Cheolwon, et al.
Publicado: (2012)

Clinicopathologic Characteristics of T-cell Non-Hodgkin's Lymphoma: A Single Institution Experience
por: Ko, Ock Bae, et al.
Publicado: (2009)

Case series of precursor B-cell lymphoblastic lymphoma
por: Kim, Jin Yong, et al.
Publicado: (2014)

CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma
por: Koh, Young Wha, et al.
Publicado: (2014)

Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma
por: Choi, Eun-Ji, et al.
Publicado: (2017)

Prophylaxis for Pneumocystis carinii pneumonia in non-Hodgkin’s lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis
por: Huang, Xiaojia, et al.
Publicado: (2023)

Assessment of cytomegalovirus and cell-mediated immunity for predicting outcomes in non-HIV-infected patients with Pneumocystis jirovecii pneumonia
por: Kim, Taeeun, et al.
Publicado: (2017)

Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma
por: Kim, Seok Jin, et al.
Publicado: (2019)

Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma
por: Jo, Jae-Cheol, et al.
Publicado: (2012)

JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma
por: Kim, Min-Sun, et al.
Publicado: (2020)

Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders–diffuse large B-cell lymphoma
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients
por: Jeong, Jae Ho, et al.
Publicado: (2017)

Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09)
por: Yoon, Dok Hyun, et al.
Publicado: (2017)

A Case of Coincident Multiple Myeloma and Non-Hodgkin’s Lymphoma
por: Lee, Geun Chan, et al.
Publicado: (1994)

Pneumocystis pneumonia occurrence and prophylaxis duration in kidney transplant recipients according to perioperative treatment with rituximab
por: Kim, Young Hoon, et al.
Publicado: (2020)

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
por: Koh, Young Wha, et al.
Publicado: (2017)

Reply: Correspondence Regarding the Article Titled “Low Lymphocyte Proportion in Bronchoalveolar Lavage Fluid as a Risk Factor Associated with the Change from Trimethoprim/sulfamethoxazole Used as First-Line Treatment for Pneumocystis jirovecii Pneumonia”
por: Kim, Tark, et al.
Publicado: (2018)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study
por: Hwang, Hee Sang, et al.
Publicado: (2021)

Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation
por: Kim, Seok Jin, et al.
Publicado: (2023)

Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems
por: Hwang, Hee Sang, et al.
Publicado: (2014)

Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma
por: Hwang, Hee Sang, et al.
Publicado: (2013)

Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy
por: Oh, Sukjoong, et al.
Publicado: (2011)

Serum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factor
por: Yoo, Changhoon, et al.
Publicado: (2014)

Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution
por: Kim, Meejeong, et al.
Publicado: (2021)

Langerhans Cell Histiocytosis Followed by Hodgkin's Lymphoma
por: Park, IK Soo, et al.
Publicado: (2012)

Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience
por: Kim, Jeongseok, et al.
Publicado: (2014)

Pneumocystis jirovecii pneumonia in HIV-uninfected, rituximab treated non-Hodgkin lymphoma patients
por: Wei, Kai-Che, et al.
Publicado: (2018)

Fatal Interstitial Pneumonitis Rapidly Developed after the First Cycle of CHOP with Etoposide Combination Chemotherapy in a Patient with Lymphoma
por: Park, Hyung Chul, et al.
Publicado: (2013)

Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient
por: Choi, Eunji, et al.
Publicado: (2015)

Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection
por: Jo, Jungmin, et al.
Publicado: (2014)

Diagnostic performance of the (1–3)-β-D-glucan assay in patients with Pneumocystis jirovecii compared with those with candidiasis, aspergillosis, mucormycosis, and tuberculosis, and healthy volunteers
por: Son, Hyo-Ju, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_6qd4rv9gidafukvqqvarbcls6t